CoreWeave targets ‘unlimited’ insurance money to fund AI build-out

CoreWeave co-founder Brannin McBee (who leads financing) says investment-grade ratings for more chip-backed debt — and eventually the company — would open insurer capital that “is unlimited… all the money in the world that sits in the insurance tranche.” Earlier this year CoreWeave closed an $8.5bn chip-backed loan with a Meta offtake, the first such loan fully rated investment-grade; it has raised more than $35bn this year across chip-backed loans, HY bonds, converts and share sales, with debt and lease obligations of about $52bn at end-June. Visible Alpha FCF consensus is about −$25bn this year (−$28bn next, −$18bn 2028); Q2 interest costs more than doubled to $640mn; debt is about 5.8x annualised Q2 EBITDA; S&P rates financial risk “aggressive.” CreditSights’ Jordan Chalfin calls the structures “very creative” but warns costs could rise (unsecured bonds yield almost 15%) and flags a lease-vs-contract duration mismatch: “If there’s an overbuild, why would [customers] renew?” Nearly all 2027 capacity is sold and the firm is signing 2028+; non-IG offtakes such as AI labs are “not ready” for the insurance tranche yet, though McBee thinks they will get there; founders sold about $2bn of shares this year (S&P Capital IQ).